J Korean Ophthalmol Soc.  2011 Mar;52(3):345-349. 10.3341/jkos.2011.52.3.345.

Comparison of the Effects Between Bevacizumab and Mitomycin C on the Survival of Fibroblasts

• Kim SH
• Kim JW

• KMID: 2214300
• DOI: http://doi.org/10.3341/jkos.2011.52.3.345

Abstract

PURPOSE
To compare the antiproliferative effects between bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), and mitomycin C in human Tenon's capsule fibroblasts.
METHODS
Primarily cultured human Tenon's capsule fibroblasts were exposed to 0, 25, 50, 100, and 200 microg/ml bevacizumab and mitomycin C, and incubated for 5 days. Cellular survival and production of nitric oxide were assessed by MTT assay and Griess assay, respectively.
RESULTS
Bevacizumab showed antiproliferative effects only at high concentrations (200 microg/ml) and revealed much less effect on the cellular survival compared to mitomycin C. In addition, bevacizumab did not affect the production of nitric oxide.
CONCLUSIONS
The antiproliferative effect of bevacizumab is much lower than mitomycin C in human Tenon's capsule fibroblasts.

Keyword

Antiproliferation; Bevacizumab; Fibroblast; Mitomycin C

MeSH Terms

Antibodies, Monoclonal, Humanized
Fibroblasts
Humans
Mitomycin
Nitric Oxide
Tenon Capsule
Vascular Endothelial Growth Factor A
Bevacizumab
Antibodies, Monoclonal, Humanized
Mitomycin
Nitric Oxide
Vascular Endothelial Growth Factor A

Figure

• 

  Figure 1. Effect of bevacizumab on the survival of human Tenon's capsule fibroblasts. bevacizumab inhibited survival of fibroblasts at high concentration (∗ p<0.05).

• 

  Figure 2. Effect of mitomycin C on the survival of human Tenon's capsule fibroblasts. Mitomycin C inhibited cellular survival significantly from low concentration (∗ p<0.05).

• 

  Figure 3. Comparison of the antiproliferative effects between bevacizumab and mitomycin C on the survival of human Tenon's capsule fibroblasts at the same concentrations. Mitomycin C showed more antiproliferative effect than bevacizumab each concentration (∗p<0.05).

• 

  Figure 4. Effect of bevacizumab on the production of nitric oxide in Tenon's capsule fibroblasts. Bevacizumab did not significantly affect on the production of nitrite (p<0.05).

Reference

References

1. Midgley R, Kerr D. Bevacizumab–current status and future directions. Ann Oncol. 2005; 16:999–1004.

2. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363–72.

3. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26:275–8.

4. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006; 26:352–4.

5. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of ru-beosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006; 26:354–6.

6. Skuta GL, Parrish RK 2nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987; 32:149–70.

7. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003; 48:314–46.

8. Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma fil-tration surgery. Invest Ophthalmol Vis Sci. 2009; 50:5217–25.

9. Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res. 1999; 41:773–80.

10. Morbidelli L, Chang CH, Douglas JG, et al. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol. 1996; 270:H411–5.

11. Crowston JG, Wang XY, Khaw PT, et al. Human serum reduces mitomycin-C cytotoxicity in human tenon's fibroblasts. Invest Ophthalmol Vis Sci. 2006; 47:946–52.

12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65:55–63.

13. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem. 1982; 126:131–8.

14. Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res. 1999; 41:773–80.

15. Dulak J, Józkowicz A, Dembinska-Kiec A, et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000; 20:659–66.

16. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiprolifer ative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007; 245:1837–42.

17. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007; 91:1230–3.

18. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114:855–9.

19. Kernt M, Welge-Lüssen U, Yu A, et al. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe. 2007; 104:965–71.

20. Kim SH, Kim JW. Effect of bevacizumab on survival and production of nitric oxide in trabecular meshwork cells. J Korean Ophthalmol Soc. 2009; 50:1404–8.

21. Schwentker A, Vodovotz Y, Weller R, Billiar TR. Nitric oxide and wound repair: role of cytokines? Nitric Oxide. 2002; 7:1–10.

22. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006; 90:1316–21.